Treatment of Restrictive Cardiomyopathy in Sarcoidosis

When restrictive cardiomyopathy occurs in the setting of sarcoidosis, establishing the underlying diagnosis is essential — it directly determines which targeted therapies are appropriate for this specific patient profile.

Clinical scenario

This protocol addresses patients with restrictive cardiomyopathy in whom sarcoidosis has been identified as the underlying or co-existing condition. Precise diagnosis in this scenario is a prerequisite for selecting the correct treatment pathway, as the causative process informs the therapeutic approach.

Treatment approach

Management in this setting involves immunosuppressive therapeutics directed at the underlying disease process.

The complete structured regimen — including the specific agents, sequencing, and monitoring targets — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehad194

Precise diagnosis is also essential for genetic phenocopies with available target treatments: ERT for Anderson–Fabry disease or glycogenosis such as Pompe disease; therapeutic phlebotomy for haemochromatosis; immunosuppressive therapeutics for sarcoidosis; new biological drugs for systemic diseases (e.g. autoimmune diseases with cardiac involvement that can reverse or stabilize by treating the disease itself); and removal of the toxic causes.

View source ↗